| Name | Title | Contact Details |
|---|---|---|
Elena McDermott |
Director, Assistant General Counsel | Profile |
Michael Rozycki |
Senior Vice President, Regulatory Affairs | Profile |
Yelena Ferreira |
Associate Director, Assistant General Counsel | Profile |
Yelena Ferreira |
Director, Assistant General Counse | Profile |
Daina Borteck |
Assistant General Counsel | Profile |
BERTRAND CHAFFEE HOSPITAL is a Springville, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
UCM Digital Health (UCM) delivers an end-to-end digital first healthcare solution that combines a digital front door platform with a 24/7 emergency medicine treat, triage and navigation telehealth service – designed to lower costs, improve outcomes and provide a better patient experience. UCM Digital Health brings together clinical expertise, advanced technology and compassionate care to offer powerful advantages for insurers, brokers, employers, patients and providers. UCM Digital Health partners with insurers, employers, patients, providers, technology solutions companies – covering every corner of the healthcare ecosystem to deliver a complete, trusted, technology-based and data-driven healthcare solution. UCM Digital Health`s unique combination of digital front door platform plus emergency medicine triage and navigation expertise allows all care to begin digitally in one place. Located in Troy, New York, UCM Digital Health was founded in 2015 by emergency clinicians Keith Algozzine, PA-C and Michael Bibighaus, M.D., in an effort to combine healthcare and technology who continue to run the operations of the company.
M J Designs is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Evaheart USA Medical, Inc. is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.